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of Liver Regeneration
Andrea Schlegel, MD,∗ Mickael Lesurtel, MD, PhD,∗ Emmanuel Melloul, MD,∗ Perparim Limani, MD,∗
Christoph Tschuor, MD,∗ Rolf Graf, PhD,∗ Bostjan Humar, PhD,∗ and Pierre A. Clavien, MD, PhD†
Objectives: To develop a reproducible animal model mimicking a novel
2-staged hepatectomy (ALPPS: Associating Liver Partition and Portal Vein
Ligation for Staged Hepatectomy) and explore the underlying mechanisms.
Background: ALPPS combines portal vein ligation (PVL) with liver transec-
tion (step I), followed by resection of the deportalized liver (step II) within
2 weeks after the first surgery. This approach induces accelerated hypertrophy
of the liver remnant to enable resection of massive tumor load. To explore
the underlying mechanisms, we designed the first animal model of ALPPS in
mice.
Methods: The ALPPS group received 90% PVL combined with parenchyma
transection. Controls underwent either transection or PVL alone. Regeneration
was assessed by liver weight and proliferation-associated molecules. PVL-
treated mice were subjected to splenic, renal, or pulmonary ablation instead
of hepatic transection. Plasma from ALPPS-treated mice was injected into
mice after PVL. Gene expression of auxiliary mitogens in mouse liver was
compared to patients after ALPPS or PVL.
Results: The hypertrophy of the remnant liver after ALPPS doubled relative to
PVL, whereas mice with transection alone disclosed minimal signs of regen-
eration. Markers of hepatocyte proliferation were 10-fold higher after ALPPS,
when compared with controls. Injury to other organs or ALPPS-plasma injec-
tion combined with PVL induced liver hypertrophy similar to ALPPS. Early
initiators of regeneration were significantly upregulated in human and mice.
Conclusions: ALPPS in mice induces an unprecedented degree of liver re-
generation, comparable with humans. Circulating factors in combination with
PVL seem to mediate enhanced liver regeneration, associated with ALPPS.
Keywords: ALPPS, PVL, Transection, novel mechanisms of regeneration,
human to mice
(Ann Surg 2014;260:839–847)
L arge or multiple liver tumors cannot be removed in many patientsbecause of insufficient size and function of the putative future
liver remnant (FLR).1,2 When extended liver resections are attempted,
the postoperative course can be complicated by the development of
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liver failure, so-called “small for size syndrome” (SFSS),1,3 which
often leads to death of the patient. Surgical strategies combining 2
operations (staged hepatectomy), including right portal vein occlusion
and wedge resections of all left-sided tumors in a first step, followed
by extended right hepatectomy in a second step 1 month or more later,
are currently considered as standard therapy by many.2,4 Portal vein
occlusion can be achieved either by portal vein ligation (PVL) or by
portal vein embolization. A drawback of this approach is the need for
long time intervals between the 2 steps, which increase the risk of
disease progression and render the second operation difficult because
of the development of diffuse adhesion.5 Another shortcoming in
some cases is the inadequate hypertrophy of the FLR and the risk of
SFSS after the completion hepatectomy during the second step.1 Both
drawbacks lead to a 30% to 40% dropout with patients, who may not
benefit from a curative resection.6,7
A novel 2-staged surgical procedure with the nickname
“ALPPS” for Associating Liver Partition and Portal vein ligation
for Staged hepatectomy8 was introduced in 2011 to overcome those
most feared complications, that is, insufficient FLR and long interval
between both steps.8,9 In ALPPS, PVL is combined with liver tran-
section during the first step, followed by resection of the deportalized
liver (second step) a few days later. This technically challenging ap-
proach has triggered an unprecedented number of comments, publica-
tion of small case series, and propositions for modification because of
consistently reported higher morbidity and mortality rates.6,10–16 To
better understand the underlying mechanisms of accelerated regener-
ation triggered by ALPPS, we developed the first model of ALPPS
in mice and tested whether such mechanisms may also be active in
humans.
METHODS
Animals
All animal experiments were performed in accordance with
Swiss Federal Animal Regulations and approved by the Veterinary
Office of Zurich. C57Bl/6 mice, aged 10 to 12 weeks, were obtained
from Harlan (NL) and used for all experiments.
Development of the ALPPS Model in Mice
(Steps I and II)
Anesthesia was induced by isoflurane inhalation (2%–4%). For
PVL, portal branches of the caudate lobe, right lobe, and right middle
lobe of the liver were individually ligated using 9-0 silk, as illustrated
in Figure 1. To achieve a 90% portal occlusion of the whole liver, the
small left lateral lobe (LLL) was removed after ligation of the pedicle
with prolene 8/0. Both the portal vein and the artery of the left middle
lobe, serving as the FLR and representing 9% to 11% of the total
liver volume, were preserved. In the ALPPS group (step I), 90% PVL
was combined with 80% liver parenchyma transection between the
deportalized right middle lobe and the normally perfused left middle
lobe, using a bipolar forceps (Fig. 1). A routine cholecystectomy was
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FIGURE 1. Surgical procedure of ALPPS (steps I and II) in mice. A, Baseline of mouse liver. B, Step I of ALPPS in mice; PVL performed
at the caudate lobe, right lobe, and right middle lobe. Note the demarcation between normally perfused left middle lobe and
portal-depleted right middle lobe, where transection is performed. In addition, the left lateral lobe is resected and standard
cholecystectomy is performed. Both vessels of the left middle lobe remain untouched. C, Two days after step I, the left middle
lobe shows significant increase in size, and step II including resection of all deportalized liver lobes is performed. D, Again, 2 days
after step II, the remnant liver shows a significantly increased regeneration (E), whereas 7 days after step II, basically a new liver
was developed, derived from initially 10% liver volume. CL indicates caudate lobe; ML, middle lobe; RL, right lobe, LLL, left lateral
lobe.
performed during step 1 surgery. The following experimental groups
for step I were included:
 ALPPS group: 90% PVL and 80% transection between right and
left middle lobes.
 PVL group: 90% PVL alone.
 Transection group: 80% parenchymal transection between right
and left middle lobes alone (as in ALPPS).
 LLL group: Resection of left lateral liver lobe. Animals in the LLL
group served as negative controls.
Each animal was clinically observed, and liver tissue and
plasma were obtained at days 1, 2, 4, and 7 after the first step (see
Supplemental Digital Content Table 1, available at http://links.lww
.com/SLA/A637). Ninety percent hepatectomy (caudate lobe, right
lobe, right middle lobe, and LLL) led to the development of SFSS,
and all animals died within 24 to 36 hours after surgery.
Step II
Animals underwent a relaparotomy 48 hours after step I to
remove the deportalized liver lobes (caudate lobe, right lobe, and
right middle lobe) (6-0 silk) (ALPPS and PVL groups). The same
lobes were resected in both other control groups (transection and
LLL groups) keeping only the left middle lobe (Fig. 1).
To explore the underlying mechanisms of regeneration of
step I, some animals underwent 90% PVL with additional partial
renal, splenic, or pulmonary bipolar ablation (mechanical burning)
instead of liver parenchyma transection, using the same bipolar de-
vice (PVL + kidney; PVL + spleen). Pulmonary bipolar ablation was
performed in the left lobe of the lung through a left-side thoracotomy,
followed by 90% PVL and abdominal closure (PVL + lung). Fur-
thermore, plasma was obtained from mice 1 hour after completion of
ALPPS step I. This sample of plasma (200μL) was injected in the in-
frahepatic vena cava in mice immediately after PVL but in absence of
other manipulations. PVL-mice, injected with sham plasma sample,
served as controls (PVL + sham plasma). To explore inflammatory
and growth response after surgery, liver tissue and plasma samples
were obtained 1 hour after step I surgery (all groups; ALPPS step I,
PVL, transection, LLL).
Human Sample Collection and Analysis
To assess the inflammatory response in patients undergoing
ALPPS, liver samples were prospectively collected at the end of the
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surgery (1 hour after ALPPS step I or PVL only). Quantitative poly-
merase chain reaction (PCR) for interleukin-6 (IL-6), tumor necrosis
factor α (TNF-α) (mRNA), was performed in these tissue samples.
Plasma samples were collected at the same time to measure circulat-
ing IL-6 in the same patients (human ALPPS step I: n = 5; human
PVL alone: n = 3). All samples were regularly included after proper
ethical approval of the patients (clinical trials.gov, NCT 01775267).
Liver Weight to Body Weight Ratio
Liver regeneration was assessed by the left middle lobe
weight to body weight ratio (FLR/BW) at days 1, 2, 4, and 7
after surgery (steps I and II). Animal weight was measured di-
rectly before harvesting. Ten animals were allocated per group and
time point (see Supplemental Digital Content Table 1, available at
http://links.lww.com/SLA/A637).
Histological Examination
Immunostainings were performed for Ki67 (Abcam), pH3
(Chemicon), F4/80 (BMA Biomedicals, Augst, Switzerland), and
Cd31 (BD Pharmingen), using the Ventana Discovery automated
staining system and the iView DAB kit (Dako North America Inc.,
Via Real Carpinteria, CA) and counterstained with hematoxylin. The
number of Ki67-positive and pH3-positive hepatocytes was deter-
mined by manual counting in 20 random visual fields (200×).
Plasma Values
Plasma samples were obtained from the infrahepatic vena cava
before organ harvesting. Plasma levels of alanine aminotransferase
and bilirubin were measured using a serum multiple biochemical an-
alyzer (Ektachem DTSCII; Johnson & Johnson Inc, Rochester, NY).
Hmgb-1-Elisa was obtained from IBL (mouse: ST51011), Factor-
V-Elisa from Cusabio (mouse: N2407272873), and IL-6-Elisa from
R&D system (mouse: Dy406; human: Dy206).
Quantitative Real-Time PCR
Total RNAwas extracted from liver tissue using Trizol reagent
(Invitrogen, Basel, Switzerland). After generation of complemen-
tary DNA (ThermoScript reverse-transcription PCR system; Invit-
rogen), quantitative real-time PCR amplification and data analy-
sis were performed on the ABI Prism 7000 Sequence Detector
System (PE Applied Biosystems, Rotkreuz, Switzerland). TaqMan
gene expression assays (PE Applied Biosystems) for IL-6 (mouse:
Mm00446190_m1, human:Hs00985639_m1) and TNF-α (mouse:
Mm0044 3258_m1;human: Hs99999043_m1) were used and nor-
malized to 18S rRNA (control reagents; PE Applied Biosystems).
Statistical Analysis
Data are expressed as mean plus standard deviation. Differ-
ences between the groups were assessed by a Mann-Whitney U test.
The level of statistical significance was set at P < 0.05. Statistical
analyses were performed using Prism 4.0 (GraphPad).
RESULTS
New Model of ALPPS in Mice (Step I)
The development of the animal model followed, as closely as
possible, the 2 steps of the ALPPS procedure (Fig. 1), as performed
in human. Animals showed normal recovery and above 90% survival
after surgery. The overall low mortality suggests that this new ap-
proach in mice does not induce liver failure, despite the application
of 90% PVL. Although serum alanine aminotransferase levels in-
creased after step I in ALPPS and PVL alone, we did not observe
any sign of liver failure such as hyperbilirubinemia, low factor V, or
increase in Hmgb-1 levels during the first week after step I (Fig. 2).
Parenchyma of FLR did not disclose any abnormalities after step I
(Fig. 2).
Based on these findings, we concluded that step I of ALPPS
model is feasible, reproducible, and does not induce relevant injury
in mouse liver.
Accelerated Liver Regeneration After Step I
We, serially, measured the weight gain of the FLR (left middle
lobe) in relation to mouse body weight within 1 week after step I.
The FLR/BW ratio indicated a significantly accelerated hypertrophy,
reaching 100%, already by day 1 after step I. In contrast, doubling of
FLR weight after PVL required at least 4 days (Fig. 3). The prolif-
erative index, assessed by Ki-67, was significantly higher in ALPPS,
when compared with other groups (Fig. 3). In addition, the ALPPS
group displayed more hepatocyte nuclei positive for pH3, a marker of
mitosis (Fig. 3). In contrast, the large nuclei, positive for pH3, were
completely absent in mice after PVL or transection alone, as well as
resection of the LLL (negative control) (Fig. 3). These results indicate
that significantly more hepatocytes enter the cell cycle earlier after
ALPPS than after PVL or any other groups. Of note, 1 week after
step I, FLR after ALPPS remained 1.5-fold larger than after PVL
(Fig. 3).
We conclude from this set of experiments that ALPPS induces
an accelerated liver hypertrophy, supported by volume increase and
hepatocyte proliferation.
ALPPS Procedure—Step II
In clinical practice, a major advantage of ALPPS remains the
possibility for earlier completion of the step II operation, that is,
removing the deportalized liver within 1 to 2 weeks after step I.5
Animals allocated to ALPPS showed normal liver remnant to body
weight ratio (LR/BW ratio) 7 days after the complete procedure (ie,
9 days after step I). The size of the remnant liver (left middle lobe) was
comparable with native livers (Fig. 4). Of note, step II was feasible in
all groups and led to 90% survival after ALPPS, PVL, or transection.
Animals allocated to the LLL group (negative control), however,
died from liver failure because of SFSS within 24 hours after step II
(Fig. 4). During step I, these animals (LLL group) did not receive
PVL or parenchyma transection, and consequently regeneration did
not occur leaving behind a too small FLR.
We concluded from these experiments that liver growth was
primed by transection, resulting in a superior liver hypertrophy than
in any other groups.
Extrahepatic Injury Mimics the Effect of Transection
in ALPPS
To explore whether transection triggers accelerated regenera-
tion because of a discontinuity between the FLR and the rest of the
liver or rather through the release of growth factors, we developed
other models including partial tissue bipolar burning (ablation) of the
kidney, spleen, or lung. In each of these groups, FLR increased in
a similar range, as in the full ALPPS model including proliferative
markers such as Ki-67 (Fig. 5).
ALPPS-Plasma Injection After PVL Triggers
Comparable Regeneration, as Original ALPPS
Plasma, obtained frommice 1 hour after completion of ALPPS
step I, was injected in PVL-treated mice alone. This maneuver in-
duced a comparable degree of liver weight gain and hepatocyte prolif-
eration, as in the ALPPS model (Fig. 5). In contrast, plasma obtained
from animal after sham laparotomy failed to induce any additional
regeneration in PVL-treated livers.
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FIGURE 2. Markers for liver function and injury after step I of ALPPS, transection or PVL. Plasma alanine aminotransferase (A),
Hmgb-1 (B), bilirubin (C), and Factor V (D) at 24 hours, 48 hours, and 168 hours after step I. Note the increased level of ALT in the
early phase after ALPPS and PVL, while bilirubin remained low during the first week after step I. Partial necrotic cell death leads to
an increase in ALT, derived from the portal-depleted liver lobes in ALPPS and PVL animals. These lobes contribute to a stable liver
function, as detected by Factor V (D). The left middle lobe in ALPPS, with preserved vessels, showed no signs of necrosis (H&E
staining, E) and exclusively liver steatosis was slightly different between ALPPS, PVL, and transection. Accordingly, macrophages
were comparable stained using M1 marker F4/80 in all groups, and endothelial lining was not increased (CD31 staining) (E). ALT
indicates alanine aminotransferase, Hmgb-1, High-Mobility-Group-Box-Protein-1.
On the basis of these experiments, we conclude that the rapid
liver volume increase after ALPPS is triggered by systemic release
of putative growth factors.
Soluble Initiators of Accelerated Liver Regeneration
After injection of ALPPS plasma in PVL-treated mice, we
performed several analysis of plasma, obtained 1 hour after ALPPS
surgery. At this early time point, animals after ALPPS contained ele-
vated plasma levels of IL-6 relative to PVL alone (see Supplemental
Digital Content Fig. 1, available at http://links.lww.com/SLA/A636).
Mice, allocated to transection, showed a comparable increase of
IL-6-plasma levels at this early time point. Accordingly, auxiliary
promoters (ie, IL-6-mRNA and TNF-α-mRNA) were significantly
upregulated in regenerating FLR 1 hour after step I of ALPPS.
Transection alone triggered a comparable upregulation of the same
genes at such early time points after surgery (see Supplemen-
tal Digital Content Fig. 1, available at http://links.lww.com/SLA/
A636).
To explore whether similar mechanisms might be active in
human, we used our prospectively intraoperatively collected blood
samples from patients, who underwent either ALPPS or PVL. We
compared gene expression of IL-6 and TNF-α in liver tissue and
plasma levels of IL-6 1 hour after step I in patients who underwent
either PVL or ALPPS. Genes related to the IL-6-TNF-α-STAT3-
pathway disclosed a significantly higher expression after ALPPS
step I than PVL alone. This finding was corroborated by a sig-
nificant increase of IL-6 in plasma after ALPPS step I relative to
PVL alone (see Supplemental Digital Content Fig. 1, available at
http://links.lww.com/SLA/A636).
Findings in animals, consistent with clinical data, suggest a
contribution of the IL-6-TNF-α-STAT3-pathway to the rapid liver
hypertrophy after ALPPS step I.
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FIGURE 3. Volume gain and proliferation markers in future liver remnants during the first week comparing ALPPS, PVL, and
transection. A, The FLR/BW indicates a significantly increased weight gain of left middle lobe already within the first 24 hours after
step I of ALPPS as compared with PVL or transection alone (FLR/BW ratio: ALPPS vs PVL: day 1: P = 0.01, day 2: P = 0.007, day
4: P = 0.05). B, Liver sections 24 hours and 48 hours post–step I stained for Ki-67 and pH3 (D). Quantification of Ki-67 (C)- and
pH3-positive cells (E) after step I in all different groups. Note the large amount of Ki-67 positive nuclei already 1 day after step I of
ALPPS (Ki-67 positive cells: ALPPS vs PVL: day 1: P < 0.0001, day 2: P = 0.0003, day 4: P = 0.001) and prominent, bold nuclei in
pH3 stains of ALPPS mice at 24 and 48 hours (D) (pH3 positive nuclei: ALPPS vs PVL: day 1: P = 0.004, day 2: P = 0.0004, day 4:
P = 0.003), while PVL-treated livers present a markedly delayed increase of Ki-67 positive nuclei in accordance with decelerated
volume increase as compared with ALPPS procedure. Error bars refer to ±SD. BW indicates body weight; ML, middle lobe; FLR,
Future Liver Remnant.
DISCUSSION
The development of an ALPPS model in mice put forward 3
main findings. First, we confirmed the unprecedented and rapid regen-
erative capacity of a small FLR after step I of the ALPPS procedure.
Second, we provide evidence suggesting that the accelerated regen-
erative ability of the FLR is due to circulatory growth factors, rather
than a discontinuity of the microcirculation after liver transection.
Third, preliminary data suggest that similar mechanisms are active in
human.
ALPPS was developed to offer an increased chance of curative
resection in patients with multiple or large liver tumors by induc-
ing accelerated hypertrophy of the FLR and reducing the delay to
completely clear the liver from tumors.6,8–10 Although some authors
confirmed the impressive and fast volume increase of the FLR after
ALPPS,8,9,11,12,15–18 others have repeatedly challenged the superior-
ity of ALPPS in triggering liver regeneration, when compared with
other approaches, such as portal vein embolization, particularly when
segment IV (four) is included in the portal occlusion.19,20 The first
aim of the newly developed model of ALPPS was, therefore, to solve
this issue. The model demonstrated that ALPPS is associated with
accelerated growth of the FLR, along with all markers of hepatocyte
proliferation, when compared with PVL alone. Interestingly, PVL
itself has been previously shown to be equal or superior to portal
vein embolization in inducing regeneration in rodent models.21,22 Al-
though the kinetic of regeneration is different in humans and rodents,
the observation of accelerated regeneration is consistent with clinical
data.8,9,15,17
There are ongoing debates concerning the underlying mecha-
nisms behind the accelerated liver regeneration induced by ALPPS.
Many have postulated that this effect relies on the discontinuation
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of “cross portal” circulation after transection between the normally
perfused and deportalized liver parts.10,11 We have speculated that
transection of the parenchyma may induce an inflammatory response
with the release of putative growth factors, which may enhance
the regenerative process. A few sets of experiments in the model
of ALPPS strongly point out to a release of proliferating factors
into the systemic circulation, which, combined with PVL, induce
the unprecedented growth of the FLR. The observation of acceler-
ated regeneration, when injecting plasma obtained from mice after
ALPPS step I to animals undergoing PVL alone strongly supports the
existence of soluble growth factors. The similar effects on regenera-
tion achieved by injuries to other organs further point out to existence
of soluble mediators of liver regeneration, additionally suggesting
that the origin of the circulating growth factors is not “liver-specific.”
Of relevance was the detection of similar enhanced release of proin-
flammatory cytokines in our samples obtained in ALPPS and PVL
patients. Despite the small sample size of patients, the dramatic
increased expression of early instigators of regeneration (eg, IL-6
and TNF-α) after ALPPS, but not after PVL alone, was consistent
with the observation in the rodent model of ALPPS. These findings
open the door for future research to identify the responsiblemolecules
triggering the accelerated regeneration.
The consistently reported higher morbidity after
ALPPS,6,10,13,14,20,23 including the development of multiorgan
failure, has discouraged many groups to use this approach. With
the observation of massive release of inflammatory factors into the
circulation, it is tempting to speculate that these mediators may be
responsible for the systemic inflammatory response syndrome, also
known as SIRS or SIRS-like syndrome,24,25 observed in several
patients after ALPPS. Surgical procedures of similar invasiveness,
that is, split liver in liver transplantation or living liver donation,
which also include a complete liver transection, were shown to
induce comparable systemic inflammation and cytokine release in
patients.26 We detected both in mice and in humans unusual increased
levels of auxiliary promoters of liver regeneration, such as IL-6 and
TNF-α, in the plasma27,28 and in the liver tissue early after step 1
of ALPPS. Such molecules are known to contribute to SIRS-like
syndrome and potentially enhance higher morbidity.29,30 In human,
however, SIRS occurred only after step II, whereas we investigated
the release of inflammatory mediators only after step I for the search
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FIGURE 5. Volume gain and proliferation markers in future liver remnants during the first week after PVL combined with ablation
of distant organs or injection of ALPPS plasma. Renal, splenic, or pulmonary ablation (A) or ALPPS plasma injection (B) together
with PVL resulted in a comparable FLR volume gain as the original ALPPS procedure. Replacement of liver parenchyma transection
by distant organ ablation or ALPPS plasma injection displayed the same number of proliferating hepatocytes, as shown by Ki-67
staining (C). BW indicates body weight.
of mechanisms of regeneration. Whether those mediators are still
present after step II and how they may influence outcomes need
further investigations.
The discrimination between molecules that induce liver re-
generation from those, which may contribute to the increased mor-
bidity, might be crucial to improve outcome after the ALPPS pro-
cedure, while preserving regeneration. Better knowledge on the
timing of release may also be decisive for future therapeutic
interventions.
Any animal model yields some limitations.31 One difference
between the ALPPS, as performed in the clinic and this mouse model,
lies in size and lobular architecture of the liver. We carefully adapted,
however, our mouse model to mimic the clinical situation. We re-
moved the LLL lobe to reduce the lobulated liver shape and achieved
90% ligation of the portal vein branches, followed by liver tran-
section. This approach led to a model comparable with ALPPS in
humans, and controls were appropriately designed to secure a neg-
ligible impact of the resection of a small part of the liver during
step I.
CONCLUSIONS
The availability of a mouse model of ALPPS, comparable with
ALPPS performed in humans, enabled to confirm the accelerated liver
regeneration associated with this procedure. The systemic release of
circulating proliferating factors related to parenchymal transection in
association with PVL seems to be crucial for the rapid and efficient
liver growth. Future work may focus on the identification of the
specificmolecules, leading to the discovery of novel pathways of liver
regeneration, and perhaps new targets to control the SIRS-associated
morbidity, while enhancing the regenerative capacity of the liver.
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DISCUSSANTS
P. Lodge (Leeds, United Kingdom):
ALPPS, the combination of associating liver partition with
portal vein ligation for staged hepatectomy, is clearly very topical,
and there has been much discussion in the past 3 years in the major
liver meetings primarily related to indications and safety and also
about the mechanisms related to the rapid future liver remnant growth
that occurs. This important work goes some way to answering these
questions. Thank you for allowing me to review the full article before
this meeting. This study represents an enormous volume of work,
amounting to experimental surgery on 563 mice, which translates
into more than 1000 surgical procedures. The experimental model
was complex and you should be congratulated on its results.
Questions:
[1] One interesting aspect is that distant organ damage, in
combination with portal vein ligation, produced future liver remnant
growth that seemed to be as rapid as it is with ALPPS. In addition,
portal vein ligation mice treated with plasma achieved equally rapid
liver hypertrophy as ALPPSmice did. This seems to relate to putative
growth factors associated with tissue damage. As this has not really
been seen to such an extent in 2-stage liver surgery, in which a right
portal vein ligation is mostly combined with a left liver resection or
an initial ablation, do you think that the amount of tissue destruction,
associated with liver transection in ALPPS, is greater because, in
reality, an ALPPS segment 4 is completely devascularized, as it loses
both its portal vein and arterial supply? Perhaps, could it be that the
degree of tissue destruction is relevant to ALPPS?
[2] In the human aspect of your study, and in the mice, you
measured IL-6 and TNF-α, which showed a rapid rise after the first
stage of ALPPS. CRP is often used as a measure of the systemic
inflammatory response after surgery. In many types of surgery, we
are not keen to see a rise in CRP, but after major liver resection, an
early rise seems to be associated with a more rapid recovery, perhaps
related to faster liver regeneration. Did you consider including CRP
in your study and have you looked at this clinically in your ALPPS
patients?
Once again, you should be congratulated on an impressive
study, which represents an enormous body of work. I would like to
thank the ESA for the opportunity to review and comment on this
article.
Response From A. Schlegel (Zurich, Switzerland):
Thank you for your compliments and questions. I would like
to start with your second question about CRP. In animals, CRP is
a poor marker of inflammation and any specific type of injury and
therefore, cannot be used reliably. In the clinical setting of ALPPS,
we did not observe significant differences in CRP levels in patients,
when compared with those, who underwent portal vein ligation.
Your first question deals with the possible role of segment IV
devascularisation inducing cytokine release and liver regeneration.
Our experimental design does not address this issue. However,
enhanced regeneration occurswithout devascularisation of a liver seg-
ment. In this setting, our experiments indeed indicate that a minimal
degree of injury is required to trigger regeneration in the liver.
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DISCUSSANTS
C. Bruns (Magdeburg, Germany):
Thank you very much for this nice, experimental article. I
just have 1 brief question. Through your experiments on mice, you
showed that Ki-67 increased after ALPPS and was, thus, a marker for
proliferation. First of all, those liverswere completely healthy,without
having been exposed to chemotherapy. This represents a problem in
your model.
You then also looked at the enlarged liver lobes, with
respect to vascularization. Did you perform H&E staining or
immunohistochemical staining, when analyzing whether enlarged
liver lobes increase blood flow associated with angiogenesis?
Response From A. Schlegel (Zurich, Switzerland):
Thank you, Professor Bruns, for your question. We agree that
the mice livers were healthy, but this actually represents an advan-
tage of such models, enabling us to assess a specific question in a
standardized manner.
We performed immunohistochemistry, that is, CD 31 stain-
ing, which targeted endothelial cells and could not detect differences,
regarding intrahepatic microvascular density or angiogenesis in the
regenerating lobe. In addition, we quantified the vascular endothe-
lial growth factor (VEGF) expression and observed no differences
during the first week after ALPPS or only portal vein ligation. Fur-
ther research will focus on underlying mechanisms of regeneration,
including endothelial cells and other nonparenchymal cells.
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